Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).

被引：0
|
作者：
van de Donk, Niels W. C. J.
Garfall, Alfred L.
Benboubker, Lotfi
Uttervall, Katarina
Groen, Kaz
Rosinol, Laura
Matous, Jeffrey V.
Vishwamitra, Deeksha
Hodin, Caroline
Stephenson, Tara
Qi, Keqin
Zuppa, Athena
Chastain, Katherine
Mateos, Maria-Victoria
机构：
[1] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands
[2] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[3] Ctr Hosp Reg Univ, Hop Bretonneau, Tours, France
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Vrije Univ, Amsterdam Univ Med Ctr, Amsterdam, Netherlands
[6] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
[7] Colorado Blood Canc Inst, Denver, CO USA
[8] Sarah Cannon Res Inst, Denver, CO USA
[9] Johnson & Johnson Innovat Med, Spring House, PA USA
[10] Johnson & Johnson Innovat Med, Antwerp, Belgium
[11] Johnson & Johnson Innovat Med, Titusville, NJ USA
[12] Johnson & Johnson Innovat Med, Raritan, NJ USA
[13] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Ctr Invest Canc IBMCC USAL, CSIC, Salamanca, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7517
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cytokine Release Syndrome in Patients Receiving Alternative Step-Up Doses of Talquetamab for Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study
    Morillo, Daniel
    Chamorro, Carmen Martinez
    Mateos Manteca, Maria-Victoria
    Costa, Luciano
    Minnema, Monique
    Sanchez, Larysa
    Hilder, Brandi
    Singh, Indrajeet
    Gong, Joy
    Lau, Bonnie W.
    Renaud, Thomas
    Rodriguez-Otero, Paula
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S74 - S75
  • [32] Updated long-term follow-up results of a phase 1b/2 study (FUMANBA-1) in patients with relapsed/refractory multiple myeloma (RRMM) treated with equecabtagene autoleucel
    Li, Chunrui
    Wang, Di
    Fang, Baijun
    Huang, He
    Li, Jianyong
    Chen, Bing
    Liu, Jing
    Ren, Hanyun
    Dong, Yujun
    Hu, Kai
    Liu, Peng
    Zhang, Xi
    Mi, Jian-Qing
    Li, Zhenyu
    Ding, Kaiyang
    Cai, Song-Bai
    Gui, Hong-Yu
    Wang, Wen
    Qiu, Lugui
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S196 - S197
  • [33] Recovery of ocular events with longer-term follow-up in the DREAMM-2 study of single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma
    Lonial, Sagar
    Nooka, Ajay K.
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim V.
    Jakubowiak, Andrzej
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 53 - 54
  • [34] Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up
    James R. Berenson
    Hank H. Yang
    Robert A. Vescio
    Youram Nassir
    Russell Mapes
    Shi-pyng Lee
    Joanna Wilson
    Ori Yellin
    Blake Morrison
    Jacqueline Hilger
    Regina Swift
    Annals of Hematology, 2008, 87
  • [35] Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up
    Berenson, James R.
    Yang, Hank H.
    Vescio, Robert A.
    Nassir, Youram
    Mapes, Russell
    Lee, Shi-pyng
    Wilson, Joanna
    Yellin, Ori
    Morrison, Blake
    Hilger, Jacqueline
    Swift, Regina
    ANNALS OF HEMATOLOGY, 2008, 87 (08) : 623 - 631
  • [36] Teclistamab, a B-cell maturation antigenxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
    Usmani, Saad Z.
    Garfall, Alfred L.
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Rosinol, Laura
    Chari, Ajai
    Bhutani, Manisha
    Karlin, Lionel
    Benboubker, Lotfi
    Pei, Lixia
    Verona, Raluca
    Girgis, Suzette
    Stephenson, Tara
    Elsayed, Yusri
    Infante, Jeffrey
    Goldberg, Jenna D.
    Banerjee, Arnob
    Mateos, Maria-Victoria
    Krishnan, Amrita
    LANCET, 2021, 398 (10301): : 665 - 674
  • [37] Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.
    Rosenbaum, Cara Ann
    Stephens, Leonor Ano
    Kukreti, Vishal
    Zonder, Jeffrey A.
    Cole, Craig
    Zimmerman, Todd M.
    Reece, Donna Ellen
    Berdeja, Jesus G.
    Severson, Erica
    Revethis, Andrea
    Wolfe, Brittany
    McDonnell, Kathryn
    Nam, Jennifer
    Griffith, Kent A.
    Jakubowiak, Andrzej J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] LONGER-TERM FOLLOW-UP OF A PHASE 1 STUDY OF PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIAS
    Cortes, J.
    Talpaz, M.
    Kantarjian, H. M.
    Shah, N. P.
    Bixby, D.
    Flinn, I. W.
    O'Hare, T.
    Hu, S.
    Rivera, V.
    Clackson, T.
    Turner, C.
    Haluska, F.
    Druker, B. J.
    Deininger, M. W.
    Mauro, M. J.
    HAEMATOLOGICA, 2014, 99 : 335 - 335
  • [39] Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study
    Lin, Yi
    Martin, Thomas, III
    Cohen, Adam D.
    Jakubowiak, Andrzej
    Jasielec, Jagoda
    Usmani, Saad Z.
    Madduri, Deepu
    Agha, Mounzer
    Stewart, A. Keith
    Singh, Indrajeet
    Zudaire, Enrique
    Yeh, Tzu-Min
    Allred, Alicia J.
    Olyslager, Yunsi
    Banerjee, Arnob
    Goldberg, Jenna D.
    Schecter, Jordan M.
    Jackson, Carolyn C.
    Deraedt, William
    Geng, Dong
    Wu, Xiaoling
    Carrasco, Marlene J.
    Akram, Muhammad
    Hossain, Farah
    Wang, Vickie
    Berdeja, Jesus G.
    Jagannath, Sundar
    BLOOD, 2020, 136
  • [40] Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study
    Jagannath, Sundar
    Richter, Joshua
    Dhodapkar, Madhav V.
    Hoffman, James E.
    Lee, Hans C.
    Suvannasankha, Attaya
    Shah, Mansi R.
    Lentzsch, Suzanne
    Zonder, Jeffrey A.
    Baz, Rachid
    Maly, Joseph J.
    Namburi, Swathi
    Wu, Ka Lung
    Pianko, Matthew
    Ye, Jing Christine
    Silbermann, Rebecca
    Min, Chang-Ki
    Vekemans, Marie-Christiane
    Munder, Markus
    Byun, Ja Min
    BLOOD, 2023, 142
12345